Genmab AS

$18.39
(as of Apr 4, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Genmab AS

Stock Price
$18.39
Ticker Symbol
GMAB
Exchange
NASDAQ

Industry Information for Genmab AS

Sector
Healthcare
Industry
Biotechnology

Company Description for Genmab AS

Country
USA
Full Time Employees
2,682

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Fundamentals for Genmab AS

Market Capitalization
$12,203,105,280
EBITDA
$7,390,000,128
Dividends per Share
P/E Ratio
10.93
Forward P/E Ratio
11.15
Earnings per Share
$1.76
Earnings per Share Estimate Next Year
Profit Margin
36.44%
Shares Outstanding
634,257,024
Percent Owned by Insiders
0.01%
Percent Owned by Institutions
9.31%
52-Week High
52-Week Low

Technical Indicators for Genmab AS

50-Day Moving Average
200-Day Moving Average
RSI
35.78
0.67

Analyst Ratings for Genmab AS

Strong Buy
2
Buy
2
Hold
5
Sell
0
Strong Sell
0

News About Genmab AS

Apr 2, 2025, 9:47 AM EST
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. See more.
Apr 1, 2025, 3:53 PM EST
Company Announcement See more.
Apr 1, 2025, 3:53 PM EST
Genmab A/S See more.
Apr 1, 2025, 10:00 AM EST
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. See more.